MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
Tenaya Therapeutics Inc. (NASDAQ: TNYA)*
Organization & Developments: Tenaya Therapeutics
Parents
Tenaya Therapeutics Inc. (NASDAQ: TNYA)*
Children
*The biotech is attacking heart disease through three different angles: gene therapy, cellular regeneration and precision medicine
2021: The series C funding will propel several preclinical programs toward the clinic, including a gene therapy for hypertrophic cardiomyopathy (HCM), as well as set up a site in the Bay Area to manufacture vectors to deliver its treatments.
2022: Tenaya Therapeutics (TNYA) Investor Presentation - Slideshow_seekingalpha.com
2023: The Take On Tenaya Therapeutics_ seekingalpha.com
2024: Tenaya advances gene therapy trial for heart condition By Investing.com
2024: Tenaya gene therapy for deadly heart condition boosts long-term survival in mice
2024: Tenaya Therapeutics Announces Updates on TN-201 Gene
2024: Tenaya Therapeutics: TN-201 Isn't The Only Shot On Goal Targeting Heart Disease
2025: Tenaya: Two Heart Disorder Data Releases Q4 2025 Brings About Major Inflection Point
Jumps
*Key People: Tenaya Therapeutics
Finance & Acquisitions: Tenaya Therapeutics